1st Quarter - Report

ARENTFOX SCHIFF LLP for CSL BEHRING

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Orphan drug exclusion within the pharmaceutical tax in the Patient Protection and Affordable Care Act Preserving Access to Orphan Drugs Act, all provisions Tax reform regarding orphan drug credit, including tax extenders

Foreign entity interest: CSL Limited, identified in the LD-1, is interested in U.S. tax policies that may affect the business of its subsidiary CSL Behring.

LobbyistCovered position, as disclosed
ROBERT BENNETT —
PHILIP ENGLISH —
NORMAN FREDERICK LENT —
DAN RENBERG —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Budget/Appropriations BUD

FY '16 Labor, Health and Human Services, Education, and Related Agencies appropriations regarding inclusion of Alpha-1 report language

Foreign entity interest: CSL Limited, identified in the LD-1, is interested in the existence of funding for programs that may affect the business of its subsidiary CSL Behring.

LobbyistCovered position, as disclosed
PHILIP ENGLISH —
DAN RENBERG —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.